DSIP vs N-Acetyl Selank
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
DSIP
DSIP (Delta Sleep Inducing Peptide) is a nonapeptide (9 amino acids) first isolated from rabbit thalamus in 1974, initially believed to directly induce slow-wave (delta) sleep. Research has since broadened its profile considerably: it modulates the HPA axis (reducing stress-driven cortisol), influences GH and LH release, demonstrates antioxidant properties, and may have cardioprotective effects. Despite decades of research, its precise receptor system remains incompletely characterized.
Full profileN-Acetyl Selank
Acetylated variant of Selank with enhanced stability and bioavailability. The N-acetyl modification protects the peptide from rapid enzymatic degradation, extending its active half-life relative to standard Selank. Provides anxiolytic, nootropic, and immunomodulatory effects comparable to or exceeding standard Selank with potentially greater duration from each dose.
Full profile| DSIP | N-Acetyl Selank | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | Delta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu | Selank-A, N-Ac-Selank, acetylated selank, N-acetyl selank |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–500mcg mcg, Once daily (evening) or every other day | 100mcg–500mcg mcg, 1–2x daily intranasal |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies) | Intranasal spray, Subcutaneous injection |
| Key side effects | Generally well-tolerated, Daytime drowsiness if dosed in morning, Mild headache, Altered dream quality (common) | Mild sedation (acute), Fatigue, Headache (rare), Nasal irritation (intranasal route) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: DSIP — Subcutaneous injection, Intranasal, Intravenous (clinical studies); N-Acetyl Selank — Intranasal spray, Subcutaneous injection.
- Frequency: DSIP is typically Once daily (evening) or every other day; N-Acetyl Selank is 1–2x daily intranasal.
- Research depth: this profile cites 3 sources for DSIP vs 2 for N-Acetyl Selank.
How each works
DSIP
DSIP does not directly trigger sleep in the simple sense originally proposed — more recent research indicates it modulates the neuroendocrine environment that facilitates sleep. Key findings: it reduces ACTH-driven cortisol elevation under stress, increases GH secretion in some models, and attenuates withdrawal severity in opioid and alcohol dependence (mechanisms unclear). DSIP demonstrates antioxidant effects and has cardioprotective properties in ischemic preconditioning models in animals. Its unique resistance to most peptidases (attributed to its unusual conformation) gives it a relatively long half-life for a nonapeptide.
N-Acetyl Selank
N-Acetyl Selank shares Selank's core mechanism — BDNF/NGF upregulation, enkephalinase inhibition, and GABA-A receptor complex modulation — with improved metabolic stability from the N-terminal acetyl group. The acetyl modification protects against aminopeptidase N and angiotensin-converting enzyme cleavage, extending the peptide's active residence time in neural tissue after intranasal administration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.